Detalhe da pesquisa
1.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet
; 403(10427): 632-644, 2024 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38246194
2.
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
N Engl J Med
; 386(24): 2261-2272, 2022 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657320
3.
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.
Future Oncol
; 18(31): 3473-3480, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36047545
4.
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Future Oncol
; 18(8): 903-913, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35073733
5.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 643-654, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857412
6.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 655-664, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857414
7.
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Br J Cancer
; 124(3): 574-580, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33087895
8.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
N Engl J Med
; 378(19): 1789-1801, 2018 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658430
9.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
J Immunother Cancer
; 12(3)2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38485189
10.
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 201: 113585, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402687
11.
Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors.
Cancers (Basel)
; 15(5)2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900175
12.
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36889810
13.
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.
Eur J Cancer
; 179: 87-97, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36509002
14.
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
Eur J Cancer
; 194: 113354, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37827067
15.
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 189: 112900, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277264
16.
Etiology of white pupillary reflex in pediatric age group.
Rom J Ophthalmol
; 66(1): 32-35, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35531443
17.
Prognostic and predictive value of ß-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 165: 97-112, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220182
18.
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
NEJM Evid
; 1(11): EVIDoa2200214, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319852
19.
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
J Immunother Cancer
; 10(7)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35793872
20.
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-ß and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
Target Oncol
; 16(4): 435-446, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34009501